Sanofi successfully prices EUR 2.0 billion bond issue
(Thomson Reuters ONE) -
Sanofi successfully prices EUR 2.0 billion bond issue
Paris, France - September 15, 2015 - Sanofi announces that it has successfully
priced its offering of EUR 2.0 billion of notes across 3 tranches:
* EUR 750 million Floating Rate Notes, due 2019, bearing interest at a
quarterly rate of 3-month Euribor + 0.30%
* EUR 500 million Fixed Rate Notes, due 2021, bearing interest at an annual
rate of 0.875%
* EUR 750 million Fixed Rate Notes, due 2025, bearing interest at an annual
rate of 1.500%
The issue is drawn under the Company's Euro Medium Term Note Programme.
The transaction enables the Group to lower its average cost of debt and extend
the average maturity of its debt.
Sanofi intends to use the net proceeds of the offering for general corporate
purposes, including the repayment of existing borrowings.
Bank of America - Merrill Lynch, HSBC, Société Générale CIB, and Unicredit were
Bookrunners for the offering.
About Sanofi
Sanofi, a global healthcare leader, discovers, develops and distributes
therapeutic solutions focused on patients' needs. Sanofi has core strengths in
diabetes solutions, human vaccines, innovative drugs, consumer healthcare,
emerging markets, animal health and Genzyme. Sanofi is listed in Paris
(EURONEXT: SAN) and in New York (NYSE: SNY).
DISCLAIMER
This communication shall not constitute an offer to sell or the solicitation of
an offer to buy nor shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any such state or
jurisdiction.
The notes have not been and will not be registered under the Securities Act and
may not be offered or sold within the United States or to, or for the account or
benefit of, U.S. persons except in certain transactions exempt from the
registration requirements of the Securities Act.
This communication is only being distributed to and is only directed at (i)
persons who are outside the United Kingdom or (ii) investment professionals
falling within Article 19(5) of the Financial Services and Markets Act 2000
(Financial Promotion) Order 2005 (the "Order") or (iii) high net worth
companies, and other persons to whom it may lawfully be communicated, falling
within Article 49(2)(a) to (d) of the Order or (iv) persons to whom an
invitation or inducement to engage in investment activity (within the meaning of
section 21 of the Financial Services and Markets Act 2000) may otherwise
lawfully be communicated or cause to be communicated (all such persons together
being referred to as "relevant persons"). The notes are only available to, and
any invitation, offer or agreement to subscribe, purchase or otherwise acquire
such notes will be engaged in only with, relevant persons. Any person who is not
a relevant person should not act or rely on this document or any of its
contents.
No prospectus (including any amendment, supplement or replacement thereto) or
any other offering material has been prepared in connection with the offering of
the notes that has been approved by the Autorité des marchés financiers or
notified to the Autorité des marchés financiers after approval by the competent
authority of another member State of the European Economic Area; no notes have
been offered or sold nor will be offered or sold, directly or indirectly, to the
public in France; the prospectus or any other offering material relating to the
notes have not been distributed or caused to be distributed and will not be
distributed or caused to be distributed to the public in France; such offers,
sales and distributions have been and shall only be made in France to persons
licensed to provide the investment service of portfolio management for the
account of third parties or to qualified investors (investisseurs qualifiés)
other than individuals, investing for their own account, all as defined in
Articles L. 411-2, L. 411-2 and D. 411-1 of the French Code monétaire et
financier.
Forward-Looking Statements
Any statements made in this communication that are not statements of historical
fact, including statements about Sanofi's beliefs and expectations are forward-
looking statements and should be evaluated as such. Forward-looking statements
include statements that may relate to Sanofi's plans, objectives, strategies,
goals, future events, future revenues or performance, and other information that
is not historical information. Sanofi does not undertake, and specifically
disclaims, any obligation or responsibility to update or amend any of the
information above except as otherwise required by law.
Additional Information:
This communication is neither an offer to purchase nor a solicitation of any
offer to sell any securities, nor shall there be any sale of securities in any
jurisdiction in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any such
jurisdiction.
--------------------------------------------------------------------------------
Contacts:
Media Relations Investor Relations
Laurence Bollack Sébastien Martel
Tel.: + (33) 1 53 77 46 46 Tel.: + (33) 1 53 77 45 45
mr(at)sanofi.com ir(at)sanofi.com
Press release (PDF):
http://hugin.info/152918/R/1951976/709909.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Sanofi via GlobeNewswire
[HUG#1951976]
Unternehmensinformation / Kurzprofil:
Datum: 15.09.2015 - 07:01 Uhr
Sprache: Deutsch
News-ID 419958
Anzahl Zeichen: 6776
contact information:
Town:
PARIS
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 164 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Sanofi successfully prices EUR 2.0 billion bond issue"
steht unter der journalistisch-redaktionellen Verantwortung von
Sanofi (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
